| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rotary Magnetic field can be generated by a spinning magnet or magnets. Or it can be implemented with 2 or more coils, power with a phase shift between them (90 deg for 2 coil implementation) (60deg for 3 coil implementation) Targets affected are mostly the same as for Magnet fields Main differences - may enhance the EPR effect allowing targeting of drugs to cancer cells - acts as wireless stirrer, especially on magnetic particles(inducing eddy currents in water media) - research for use in nano surgery, and mechanical destruction of cancer cells - continue to highlight ability to raise ROS in cancer cell and lower ROS in normal cells - RMF may be responsible for Ca2+ distribution to pass across the plasma membrane(differental affected for cancer and normal cells) Pathways: - induce ROS production in cancer cells, while decreasing ROS in normal cells. Ca2+ is critical and the Ca2+ balance is increased in cancer cells while decreased in normal cells (example for wound healing) - ROS↑ related: MMP↓(ΔΨm), Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx, - Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑, - lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : TNF-α↓, IL-6↓, - inhibit Growth/Metastases : TumMeta↓, TumCG↓, MMPs↓, MMP2↓, MMP9↓, IGF-1↓, RhoA↓, NF-κB↓, TGF-β↓, ERK↓ - cause Cell cycle arrest : TumCCA↑, - inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, ERK↓, - Others: PI3K↓, AKT↓, Wnt↓, AMPK, ERK↓, JNK, - Synergies: < Others(review target notes), Neuroprotective, Cognitive, - Selectivity: Cancer Cells vs Normal Cells Rotating Magnetic Fields
Time-Scale Flag: TSF = P / R / G P: 0–30 min (physical / electron / radical effects) R: 30 min–3 hr (redox signaling & stress response) G: >3 hr (gene-regulatory adaptation)MPTP: opening represents a mitochondrial commitment event integrating ROS and Ca²⁺ stress; sustained opening indicates irreversible bioenergetic failure. |
| Source: HalifaxProj(inhibit) |
| Type: |
| (Prev called GRO1 oncogene)(KC) belongs to the CXC The chemokine ligand 1 (CXCK1) is a small peptide belonging to the CXC chemokine family that acts as a chemoattractant for several immune cells, especially neutrophils or other non-hematopoietic cells to the site of injury or infection and plays an important role in regulation of immune and inflammatory responses. CXCL1 is increased in ovarian cancer via GRB2-associated binding protein 2-dependent autocrine way, promoting tumour cells proliferation and angiogenesis; Keratinocyte-derived chemokine (KC) belongs to the CXC family and it is homologous to interleukin (IL)-8. The CXC chemokines can be further divided into two main subgroups based on the presence or absence of the ELR (Glu-Leu-Arg) motif: 1. ELR+ CXC Chemokines: These include chemokines such as CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8 (IL-8), and CXCL12 (SDF-1). They are primarily involved in promoting angiogenesis, recruiting neutrophils, and facilitating tumor growth. 2. ELR- CXC Chemokines: This subgroup includes chemokines like CXCL4, CXCL9, CXCL10, and CXCL11. These chemokines are often associated with anti-tumor immunity and can attract T cells and other immune cells to the tumor microenvironment. CXC chemokines, particularly the ELR+ subset, can promote tumor growth by enhancing angiogenesis. CXC chemokines are involved in the metastatic spread of cancer cells. For example, CXCL12 and its receptor CXCR4 are known to play significant roles in the migration of cancer cells to distant sites, such as the bone marrow and lymph nodes. Given their roles in cancer progression, CXC chemokines and their receptors are being investigated as potential therapeutic targets. |
| 228- | MFrot, | MF, | Rotating magnetic field ameliorates experimental autoimmune encephalomyelitis by promoting T cell peripheral accumulation and regulating the balance of Treg and Th1/Th17 |
| - | NA, | MS, | NA |
| 221- | MFrot, | MF, | Low Frequency Magnetic Fields Enhance Antitumor Immune Response against Mouse H22 Hepatocellular Carcinoma |
| - | in-vivo, | Liver, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:192 Target#:72 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid